Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership

LA HABRA, Calif. & COLUMBUS, Ohio--(BUSINESS WIRE)--Oculogenex, a biotech company developing a novel adeno-associated viral (AAV) gene therapy treatment to stop the degeneration of central vision in patients, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership to help support the advancement of Oculogenex’s gene therapy program for dry age-related macular degeneration (AMD) toward clinical trials. Forge wil